Linked Life Data

16629421

Source:http://linkedlifedata.com/resource/pubmed/id/16629421

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-4-24
pubmed:abstractText
The IMPACT study demonstrated the benefit of interferon beta-1a (IFNbeta-1a, Avonex) two-year change in disability measured by the Multiple Sclerosis Functional Composite (MSFC) in secondary progressive multiple sclerosis (SP-MS) and health-related quality of life (HRQoL) measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI). The IMPACT data permit a detailed assessment of the relation between clinical and self-reported measures.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1352-4585
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
180-6
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study.
pubmed:affiliation
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA. millerd@ccf.org
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Multicenter Study